Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR5 | P51681 | 5/20 | 0.34 |
| ▸ | PRMT5 | O14744 | 6/20 | 0.33 |
| ▸ | THRA | P10827 | 1/20 | 0.33 |
| ▸ | VDR | P11473 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GUCY1A1 | Q02108 | 1/20 | 0.32 |
| ▸ | GUCY1B1 | Q02153 | 1/20 | 0.32 |
| ▸ | FASN | P49327 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10179508 | 0.90 | STAT3 (0.34) | CCR5PRMT5MCHR1EGLN1SLC18A3 | |
| SCHEMBL10179510 | 0.90 | STAT3 (0.34) | CCR5PRMT5MCHR1EGLN1SLC18A3 | |
| SCHEMBL10179612 | 0.89 | WNT3A (0.42) | KMT2A | |
| SCHEMBL10181998 | 0.87 | PRMT5 (0.35) | CCR5PRMT5THRAMCHR1EGLN1 | |
| SCHEMBL10181903 | 0.83 | FASN (0.35) | PRMT5THRAMCHR1EGLN1GUCY1A1 | |
| SCHEMBL10179966 | 0.82 | THRB (0.41) | PRMT5THRAVDRKMT2A | |
| SCHEMBL10179970 | 0.82 | THRB (0.41) | PRMT5THRAVDRKMT2A | |
| SCHEMBL10179902 | 0.81 | ALDH1A1 (0.36) | EGLN1 | |
| SCHEMBL10203530 | 0.80 | DDB1 (0.41) | — | |
| SCHEMBL14142023 | 0.80 | EGLN1 (0.35) | CCR5THRAVDREGLN1SLC18A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | NIPPON CHEMIPHAR CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| EP-2474540-A1 | GPR119 AGONIST | Nippon Chemiphar Co., Ltd. (JP) | 2012-07-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245344-A1 | GPR119 AGONIST | GPR119, GPR4, GPR55 | CCR5 327/4885PRMT5 1363/4885THRA 413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.